Biochem J 1964
3 Strong Oncology & Specialty Momentum: Beyond neuroscience, BMSs growth portfolio delivered $6.9B, led by: OPDIVO (nivolumab) US HCP: $2.5B (+8%) Breyanzi (lisocabtagene maraleucel) HCP: $359M (+58%) CAMZYOS (mavacamten) US HCP: $296M (+88%) These results reinforce BMSs transformation into a data-rich, diversified biopharma, with pivotal readouts expected in 2026 across fibrosis, multiple myeloma, and autoimmune indications
Programs are monthly with no long-term contract pause or stop anytime under medical guidance
Russo L, Lumeng CN (2018) Properties and functions of adipose tissue macrophages in obesity
Extras: On-demand, perfect for booking the morning after events, holidays, or parties
Kysse was shown to last 9-12 months in the lips during a clinical study